• Publications
  • Influence
New developments in our understanding of acne pathogenesis and treatment
A summarized update of the current knowledge of the pathobiology of acne vulgaris and new treatment concepts that have emerged in the last 3 years is provided.
Epidemiology of Adamantiades-Behçet's disease.
  • C. Zouboulis
  • Medicine
    Annales de medecine interne
  • 1 October 1999
Male gender, early development of the disease, and HLA-B51 positivity are markers of severe prognosis (mortality rates of 0-6%), which indicate environmental triggering of a genetically determined disorder.
Mucocutaneous Lesions of Behçet's Disease
The various lesions that constitute Behçet's disease are described and their recognition may permit earlier diagnosis and treatment, with salutary results.
Epidemiological features of Adamantiades-Behçet's disease in Germany and in Europe.
The German Registry of Adamantiades-Behçet's disease was founded in 1990 in Berlin and it provides current data on the epidemiology, the clinical manifestations and the course of the disease in
Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Adalimumab dosed once per week alleviates moderate to severe HS and significantly greater improvements in patient-reported outcomes and pain were seen in the weekly dosing group than in the placebo group.
Sexual hormones in human skin.
Estrogen-progestin treatment can reduce the need for shaving by half and arrest progression of hirsutism of various etiologies, but do not necessarily reverse it.
Establishment and characterization of an immortalized human sebaceous gland cell line (SZ95).
SZ95 is an immortalized human facial sebaceous gland cell line that shows the morphologic, phenotypic and functional characteristics of normal human sebocytes.
Acne and sebaceous gland function.
  • C. Zouboulis
  • Biology, Medicine
    Clinics in dermatology
  • 1 September 2004
Prevalence, severity, and severity risk factors of acne in high school pupils: a community-based study.
Acne is a common disorder in Iranian adolescents, with a low rate of moderate to severe acne, and a genetic background is suggested, with mother's acne history being the most important prognostic factor.
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
Treatment with adalimumab (40 mg weekly), as compared with placebo, resulted in significantly higher clinical response rates in both trials at 12 weeks; rates of serious adverse events were similar in the study groups.